Our Leadership Team
Leveraging combined expertise.
DHT was established by Sam Bristow and George Morgan. Their aim was to bridge the gap between pharmaceutical innovation and the real-world needs of patients and their families. With a deep passion for data-driven solutions, they began by developing the PIVOT methodology in collaboration with patient advocacy groups and lived experience experts, laying the foundation to build upon.
Today, DHT combines cutting-edge research, patient-centred insights, and collaboration to create meaningful change for those impacted by a health condition.
Their vision is a world where individuals with a health condition, benefit from much-needed research, high quality data, and personalised healthcare solutions.
"
For a number of years DHT has been a strategic partner to the Haemophilia Society, a UK charity that supports people with genetic bleeding disorders.
Their expertise in evidence based decision making has helped us demonstrate our impact, secure funding and give people with bleeding disorders greater understanding of an access to the best treatment options available.
Kate Burt - CEO at The Haemophilia Society
Our Mission
Our mission is to drive change in rare & unmet diseases by addressing challenges through high-quality research and data, robust analysis and actionable evidence.
.jpg)
Committed to the patient
We place patients at the heart of everything we do. At the same time, we recognise that rare & unmet conditions affect a broad range of stakeholders. Our research is designed to capture these diverse perspectives, ensuring that the experiences and needs of all those impacted are reflected.
To drive meaningful change, we bring together a wide network of stakeholders; patients, caregivers, clinicians, the life sciences industry, patient organisations, and policy makers. Creating collaborative solutions grounded in real-world insight.
